MBTPS1 and major depressive disorder: In a recent article, Guo et al. [227] have shown that the pharmacological blockage of S1PRs in the CMS model alleviated depressive-like behavior, hippocampal damage, inflammation, and oxidative stress due to NLRP3 inflammasome activation, highlighting the involvement of the S1P pathway, particularly its actions on the immune system, in MDD etiology.